- A new study led by Dana-Farber researchers shows Venclexta, the first of a new class of drugs that targets cancer cells’ survival proteins, achieved responses in patients with acute myelogenous leukemia (AML) who had relapsed or were resistant to or couldn’t tolerate chemotherapy.
- Men with testicular cancer who were uninsured or on Medicaid had a higher risk of death from what is normally a curable disease than insured patients, a new study from Dana-Farber researchers found.
- Dana-Farber Cancer Institute has monetized a portion of its interest in royalties defined by certain licensing agreements related to its Programmed Death Ligand-1 (PD-L1) intellectual property.
Tags: Funding, Immunotherapy
- Dana-Farber/Brigham and Women’s Cancer Center has been named the best for cancer care in New England for the 16th straight year, and fourth overall in the country by U.S. News & World Report.
- The Stamford Hospital Carl & Dorothy Bennett Cancer Center is the newest member of the Dana-Farber/Brigham and Women’s Cancer Care Collaborative (DF/BWCCC), and the first in Connecticut, Dana-Farber Cancer Institute and Brigham and Women’s Hospital announced today. Participation in the collaborative reflects the Bennett Cancer Center’s demonstrated commitment to excellence by meeting a wide array of standards and best practices.
- Dana-Farber Cancer Institute study published in the New England Journal of Medicine suggests that using repeated doses of an immunotherapy drug can restore a complete remission for some relapsed stem cell transplant recipients.
Tags: Leukemia, Lymphoma, Immunotherapy
- Investigators at Dana-Farber have identified a natural molecular pathway that enables cells to burn off calories as heat rather than store them as fat.
- For the third year in a row, U.S. News & World Report named Dana-Farber/Boston Children's Cancer and Blood Disorders Center the nation's #1 pediatric cancer program in its new 2016-17 Best Children's Hospitals rankings.
Tags: ChildhoodCancer, Honors
- Researchers find cytoreductive nephrectomy may offer an overall survival benefit to patients with metastatic kidney cancer who are treated with targeted therapies.
Tags: Surgery, TargetedTherapy
- The Harvard Stem Cell Institute (HSCI), three of Harvard’s clinical affiliates, including Dana-Farber Cancer Institute (DFCI), and a biopharmaceutical company have formed a unique collaboration to establish the Boston Autologous Islet Replacement Program (BAIRT) to accelerate a cure for diabetes.
Tags: BasicResearch, StemCellTransplant
Showing 1-10 of 707 items